Document Type

Article

Publication Date

12-1-2022

Publication Title

Hepat Oncol

Abstract

AIM: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.

MATERIALS & METHODS: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.

RESULTS: Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy.

CONCLUSION: This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.

PubMed ID

37009420

Volume

9

Issue

4

First Page

45

Last Page

45

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.